Cancer Immunology, Immunotherapy

, Volume 31, Issue 6, pp 358–364 | Cite as

Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: Diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2

  • Futoshi Okada
  • Masuo Hosokawa
  • Junji Hasegawa
  • Makoto Ishikawa
  • Itsuo Chiba
  • Yayoi Nakamura
  • Hiroshi Kobayashi
Original articles

Summary

We have previously reported that both regressor (QR) and progressor (metastatic, QP) clones were obtained after the in vitro exposure of a mouse fibrosarcoma BMT-11 cl-9 to quercetin [17]. In this study, we investigated possible mechanisms of spontaneous regression of QR clones as compared with tumorigenic QP and BMT-11 cl-9 tumor clones. We observed that BMT-11 cl-9 cells produced relatively high amounts of prostaglandin E2 (PGE2) during in vitro culture. The average production by 11 subclones of BMT-11 cl-9 cells was 9236±2829 pg/ml whereas that by 9 QR clones was 3411±2213 pg/ml (P <0.02). Indomethacin not only inhibited in vitro PGE2 synthesis by QP clones (high-PGE2 producers) but also the s.c. growth of QP clones in mice. Chronological changes in host immune responses to tumor-associated antigen were measured by cytotoxic T lymphocyte (CTL) activity examined after mixed lymphocyte/tumor cell culture of spleen cells obtained from tumor-bearing mice. The CTL activity disappeared abruptly in the spleen of QP-clonebearing mice 21 days after the inoculation of tumors, whereas the spleen cells of QR-clone-inoculated mice retained their CTL activity. We determined that the mechanism responsible for the regression of these regressor clones is not due to any qualitative or quantitative increase in pre-existing membrane antigens, nor the emergence of new antigen(s) on the cell surface of the QR clones; nor was it due to enhanced susceptibility of QR clones to natural killer cells, lymphokine-activated killer cells and macrophages. These finding suggest that the regression mechanism of QR clones may be the diminished inhibition of host response to tumor-associated antigen caused by the reduced production of PGE2 by QR clones.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balch CM, Dougherty PA, Cloud GA, Tilden AB (1984) Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95: 71Google Scholar
  2. 2.
    Bennett A, Del Tacca M, Stamford IF, Zebro T (1977) Prostaglandins from tumors of human large bowel. Br J Cancer 35: 881Google Scholar
  3. 3.
    Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF (1977) Prostaglandins and breast cancer. Lancet ii: 624Google Scholar
  4. 4.
    Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A (1970) Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci USA 66: 1089Google Scholar
  5. 5.
    Boon T, Kellermann O (1977) Rejection by syngeneic mice of cell variants obtained by mutagenesis of malignant teratocarcinoma cell line. Proc Natl Acad Sci USA 74: 272Google Scholar
  6. 6.
    Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchard M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T-lymphocyte-mediated cytolysis. J Exp Med 152: 1184Google Scholar
  7. 7.
    Carlow D, Kerbel R, Feltis T, Elliott B (1985) Enhanced expression of Class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. J Natl Cancer Inst 75: 291Google Scholar
  8. 8.
    Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P (1987) In situ augmentation of Class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma. Cancer Res 47: 4915Google Scholar
  9. 9.
    Frost P, Kerbel R, Bauer E, Tartamella-Biondo R, Cefalu W (1983) Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43: 125Google Scholar
  10. 10.
    Frost P, Liteplo RG, Donaghue T, Kerbel RS (1984) Selection of strongly immunogenic “tum-” variants from tumors at high frequency using 5-azacytidine. J Exp Med 159: 1491Google Scholar
  11. 11.
    Fulton A, Roi L, Howard L, Russo J, Brooks S, Brennan MJ (1982) Tumor-associated prostaglandins in patients with primary breast cancer: relationship to clinical parameters. Breast Cancer Res Treat 2: 331Google Scholar
  12. 12.
    Gorelik E, Peppoloni S, Overton R, Herberman RB (1985) Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-Methyl-N′-nitronitrosoguanidine. Cancer Res 45: 5341Google Scholar
  13. 13.
    Goronzy J, Weyand CM, Fathman CG (1986) Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. J Exp Med 164: 911Google Scholar
  14. 14.
    Herrman K (1976) Flavonols and flavones in food plants: a review. J Food Technol 11: 433Google Scholar
  15. 15.
    Hosokawa M, Okayasu T, Ikeda K, Katoh H, Suzuki Y, Kobayashi H (1983) Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune response to virus-associated antigens produced on immunizing cells. Cancer Res 43: 2301Google Scholar
  16. 16.
    Ishikawa M, Hosokawa M, Oh-hara N, Niho Y, Kobayashi H (1987) Marked granulocytosis in C57BL/6 mice bearing a transplanted BMT-11 fibrosarcoma. J Natl Cancer Inst 78: 567Google Scholar
  17. 17.
    Ishikawa M, Okada F, Hamada J-I, Hosokawa M, Kobayashi H (1987) Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine. Int J Cancer 39: 338Google Scholar
  18. 18.
    Jaffe BM (1974) Prostaglandins and cancer: an Update. Prostaglandins 6: 453Google Scholar
  19. 19.
    Kerbel RS, Frost P, Liteplo R, Carlow DA, Elliott BE (1984) Possible epigenetic mechanisms of tumor progression: induction of highfrequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol Suppl 3: 87Google Scholar
  20. 20.
    Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30: 279Google Scholar
  21. 21.
    Kobayashi H (1986) The biological modification of tumor cells as a means of inducing their regression: an overview. J Biol Resp Modifiers 5: 1Google Scholar
  22. 22.
    Kobayashi H, Sendo F, Shirai T, Kaji H, Kodama T, Saito H (1969) Modification in growth of transplantable rat tumors exposed to Friend virus. J Natl Cancer Inst 32: 413Google Scholar
  23. 23.
    Kobayashi H, Sendo F, Kaji H, Shirai T, Saito H, Takeichi N, Hosokawa M, Kodama T (1970) Inhibition of transplantable rat tumors by immunization with identical tumor cells infected with Friend virus. J Natl Cancer Inst 44: 11Google Scholar
  24. 24.
    Kobayashi H, Kodama T, Gotohda E (1977) Xenogenization of tumor cells. Hokkaido Univ Med Libr Ser 9: 1Google Scholar
  25. 25.
    Kripke ML (1981) Immunologic mechanism in UV radiation carcinogenesis. Adv Cancer Res 34: 69Google Scholar
  26. 26.
    Kuzumaki N, Fenyo EM, Giovanella B, Klein G (1978) Increased immunogenicity of low-antigenic rat tumors after superinfection with endogenous murine C-type virus in nude mice. Int J Cancer 21: 62Google Scholar
  27. 27.
    Lanni L, Becker EL (1985) Inhibition of neutrophil phospholipase A2 by p-bromophenylacyl bromide, nordihydroguaiaretic acid, 5, 8, 11, 14-eicosatetrayenoic acid and quercetin. Int Archs Allergy appl Immun 76: 214Google Scholar
  28. 28.
    Lee TP, Matteliano ML, Middleton E Jr (1982) Effect of quercetin on human polymorphonuclear leukocyte lysosomal enzyme release and phospholipid metabolism. Life Science 31: 2765Google Scholar
  29. 29.
    MacGregor JT (1986) Mutagenic and carcinogenic effects of flavonoids. Prog Clin Biol Res 213: 411Google Scholar
  30. 30.
    Nakayasu M, Sakamoto H, Terada M, Nagao M, Sugimura T (1986) Mutagenicity of quercetin in chinese hamster lung cells in culture. Mutat Res 174: 79Google Scholar
  31. 31.
    Pelus LM, Bockman RS (1979) Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol 123: 2118Google Scholar
  32. 32.
    Peppoloni S, Herberman RB, Gorelik E (1985) Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Cancer Res 45: 2560Google Scholar
  33. 33.
    Plescia OJ, Pontieri GM, Brown J, Racis S, Ippoliti F, Bellelli L, Sezzi ML, Lipari M (1984) Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors. Prostaglandins Leukotrienes Med 16: 205Google Scholar
  34. 34.
    Puccetti P, Romani L, Fioretti MC (1987) Chemical xenozgenization of experimental tumors. Cancer Metast Rev 6: 93Google Scholar
  35. 35.
    SAS User's Guide (1985): Statistics, version 5 edition. Institute Inc., NC, USA ISBN, p 470Google Scholar
  36. 36.
    Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T (1984) The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody response to tumor antigens by vaccinia virus reactive helper T cell. Eur J Immunol 14: 839Google Scholar
  37. 37.
    Van Pel A, Vessiere F, Boon T (1983) Protection against two spontaneous mouse leukemias confferred by immunogenic variants obtained by mutagenesis. J Exp Med 157: 1992Google Scholar
  38. 38.
    Yamaguchi H, Moriuchi T, Hosokawa M, Kobayashi H (1982) Increased or decreased immunogenicity of tumor-associated antigen according to the amount of virus-associated antigen in rat tumor cells infected with Friend virus. Cancer Immunol Immunother 12: 119Google Scholar
  39. 39.
    Yoshida MA, Sasaki M, Sugimura K, Kawachi T (1980) Cytogenic effects of quercetin on cultured mammalian cells. Proc Jap Acad 56(b): 443Google Scholar
  40. 40.
    Young MR, Hoover CS (1986) Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma. JNCI 77: 425Google Scholar
  41. 41.
    Young MR, Knies S (1984) Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. JNCI 72: 919Google Scholar
  42. 42.
    Young MR, Newby M (1986) Enhancement of Lewis lung carcinoma cell migration by prostaglandin E2 produced by macrophages. Cancer Res 46: 160Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Futoshi Okada
    • 1
  • Masuo Hosokawa
    • 1
  • Junji Hasegawa
    • 1
  • Makoto Ishikawa
    • 1
  • Itsuo Chiba
    • 1
  • Yayoi Nakamura
    • 1
  • Hiroshi Kobayashi
    • 1
  1. 1.Laboratory of Pathology, Cancer InstituteHokkaido University School of MedicineSapporoJapan

Personalised recommendations